Inhibition of androgen-independent prostate cancer cell growth is enhanced by combination therapy targeting Hedgehog and ErbB signalling

Cancer Cell International

Volumn 8, Issue , 2008, Pages

  Shaw, Greg ^a,b   Prowse, David M ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b WHITTINGTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; CYCLOPAMINE; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; LAPATINIB; SONIC HEDGEHOG PROTEIN;

ADULT; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL GROWTH; CELL ISOLATION; CELL PROLIFERATION; CELL STRAIN LNCAP; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; MALE; PROSTATE CANCER; PROTEIN TARGETING; SIGNAL TRANSDUCTION;

EID: 42449164689     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-8-3     Document Type: Article

References (30)

1. Carson CC 3rd Carcinoma of the prostate: Overview of the most common malignancy in men N C Med J 2006, 67(2):122-127. 16752715
2. Sakr WA Grignon DJ Crissman JD Heilbrun LK Cassin BJ Pontes JJ Haas GP High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: An autopsy study of 249 cases In Vivo 1994, 8(3):439-443. 7803731
3. Shaw GL Wilson P Cuzick J Prowse DM Goldenberg SL Spry NA Oliver T International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: A meta-analysis of 1446 patients BJU Int 2007, 99(5):1056-1065. 10.1111/j.1464-410X.2007.06770.x 17346277
4. Petrylak DP Tangen CM Hussain MH Lara PN Jr. Jones JA Taplin ME Burch PA Berry D Moinpour C Kohli M Benson MC Small EJ Raghavan D Crawford ED Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 2004, 351(15):1513-1520. 10.1056/NEJMoa041318 15470214
5. Shamash J Dancey G Barlow C Wilson P Ansell W Oliver RT Chlorambucil and lomustine (CL56) in absolute hormone refractory prostate cancer: re-induction of endocrine sensitivity an unexpected finding Br J Cancer 2005, 92(1):36-40. 10.1038/sj.bjc.6602263 15570307
6. Mimeault M Batra SK Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies Carcinogenesis 2006, 27(1):1-22. 10.1093/carcin/bgi229 16195239
7. Shi Y Brands FH Chatterjee S Feng AC Groshen S Schewe J Lieskovsky G Cote RJ Her-2/neu expression in prostate cancer: High level of expression associated with exposure to hormone therapy and androgen independent disease J Urol 2001, 166(4):1514-1519. 10.1016/ S0022-5347(05)65822-3 11547123
8. Shah RB Ghosh D Elder JT Epidermal growth factor receptor (ErbB1) expression in prostate cancer progression: Correlation with androgen independence Prostate 2006, 66(13):1437-1444. 10.1002/pros.20460 16741920
9. Nishio Y Yamada Y Kokubo H Nakamura K Aoki S Taki T Honda N Nakagawa A Saga S Hara K Prognostic significance of immunohistochemical expression of the HER-2/neu oncoprotein in bone metastatic prostate cancer Urology 2006, 68(1):110-115. 10.1016/j.urology.2006.01.060 16806433
10. Canil CM Moore MJ Winquist E Baetz T Pollak M Chi KN Berry S Ernst DS Douglas L Brundage M Fisher B McKenna A Seymour L Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: A trial of the National Cancer Institute of Canada-Clinical Trials Group J Clin Oncol 2005, 23(3):455-460. 10.1200/JCO.2005.02.129 15659491
11. Karhadkar SS Bova GS Abdallah N Dhara S Gardner D Maitra A Isaacs JT Berman DM Beachy PA Hedgehog signalling in prostate regeneration, neoplasia and metastasis Nature 2004, 431:7009-707. 712 10.1038/ nature02962 15361885
12. Datta S Datta MW Sonic Hedgehog signaling in advanced prostate cancer Cell Mol Life Sci 2006, 63(4):435-448. 10.1007/s00018-005-5389-4 16389455
13. Cristofanilli M Hayes DF Budd GT Ellis MJ Stopeck A Reuben JM Doyle GV Matera J Allard WJ Miller MC Fritsche HA Hortobagyi GN Terstappen LW Circulating tumor cells: A novel prognostic factor for newly diagnosed metastatic breast cancer J Clin Oncol 2005, 23(7):1420-1430. 10.1200/ JCO.2005.08.140 15735118
14. Moreno JG Miller MC Gross S Allard WJ Gomella LG Terstappen LW Circulating tumor cells predict survival in patients with metastatic prostate cancer Urology 2005, 65(4):713-718. 10.1016/ j.urology.2004.11.006 15833514
15. O'Hara SM Moreno JG Zweitzig DR Gross S Gomella LG Terstappen LW Multigene reverse transcription-PCR profiling of circulating tumor cells in hormone-refractory prostate cancer Clin Chem 2004, 50(5):826-835. 10.1373/clinchem.2003.028563 14988224
16. van Bokhoven A Varella-Garcia M Korch C Johannes WU Smith EE Miller HL Nordeen SK Miller GJ Lucia MS Molecular characterization of human prostate carcinoma cell lines Prostate 2003, 57(3):205-225. 10.1002/ pros.10290 14518029
17. Thalmann GN Anezinis PE Chang SM Zhau HE Kim EE Hopwood VL Pathak S von Eschenbach AC Chung LW Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer Cancer Res 1994, 54(10):2577-2581. 8168083
18. Linja MJ Savinainen KJ Saramaki OR Tammela TL Vessella RL Visakorpi T Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer Cancer Res 2001, 61(9):3550-3555. 11325816
19. Litvinov IV De Marzo AM Isaacs JT Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling? J Clin Endocrinol Metab 2003, 88(7):2972-2982. 10.1210/jc.2002-022038 12843129
20. Gaddipati JP McLeod DG Heidenberg HB Sesterhenn IA Finger MJ Moul JW Srivastava S Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers Cancer Res 1994, 54(11):2861-2864. 8187068
21. Mimeault M Moore E Moniaux N Henichart JP Depreux P Lin MF Batra SK Cytotoxic effects induced by a combination of cyclopamine and gefitinib, the selective hedgehog and epidermal growth factor receptor signaling inhibitors, in prostate cancer cells Int J Cancer 2006, 118(4):1022-1031. 10.1002/ijc.21440 16108016
22. Liu Y Majumder S McCall W Sartor CI Mohler JL Gregory CW Earp HS Whang YE Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer Cancer Res 2005, 65(8):3404-3409. 15833875
23. Festuccia C Gravina GL Angelucci A Millimaggi D Muzi P Vicentini C Bologna M Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro Int J Cancer 2005, 115(4):630-640. 10.1002/ijc.20917 15700310
24. Chou TC Talalay P Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv Enzyme Regul 1984, 22:27-55. 10.1016/0065-2571(84)90007-4 6382953
25. Mimeault M Venkatraman G Johansson SL Moore E Henichart JP Depreux P Lin MF Batra SK Novel combination therapy against metastatic and androgen-independent prostate cancer by using gefitinib, tamoxifen and etoposide Int J Cancer 2007, 120(1):160-169. 10.1002/ijc.22268 17013895
26. Sheng T Li C Zhang X Chi S He N Chen K McCormick F Gatalica Z Xie J Activation of the hedgehog pathway in advanced prostate cancer Mol Cancer 2004, 3:29. 524523 15482598 10.1186/1476-4598-3-29
27. Kasper M Schnidar H Neill GW Hanneder M Klingler S Blaas L Schmid C Hauser-Kronberger C Regl G Philpott MP Aberger F Selective modulation of Hedgehog/GLI target gene expression by epidermal growth factor signaling in human keratinocytes Mol Cell Biol 2006, 26(16):6283-6298. 1592816 16880536 10.1128/MCB.02317-05
28. Sugita S Kawashima H Tanaka T Kurisu T Sugimura K Nakatani T Effect of type I growth factor receptor tyrosine kinase inhibitors on phosphorylation and transactivation activity of the androgen receptor in prostate cancer cells: Ligand-independent activation of the N-terminal domain of the androgen receptor Oncol Rep 2004, 11(6):1273-1279. 15138566
29. Bonaccorsi L Carloni V Muratori M Formigli L Zecchi S Forti G Baldi E EGF receptor (EGFR) signaling promoting invasion is disrupted in androgen-sensitive prostate cancer cells by an interaction between EGFR and androgen receptor (AR) Int J Cancer 2004, 112(1):78-86. 10.1002/ ijc.20362 15305378
30. Ziada A Barqawi A Glode LM Varella-Garcia M Crighton F Majeski S Rosenblum M Kane M Chen L Crawford ED The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial Prostate 2004, 60(4):332-337. 10.1002/pros.20065 15264245